

## CURRICULUM VITAE

Paul Dennis Miller, M.D., F.A.C.P.

Date of birth: November 9, 1943  
Place of birth: Hagerstown, Maryland  
Married: Linda Miller  
Children: Kimberly, 1969; Jennifer, 1972;  
Kristin, 1974; Brittany, 1990; Devon, 1991

Citizenship: USA

Former Position: Partner, Western Nephrology 1976-92

Current Position: Medical Director  
Colorado Center for Bone Research (solo private practice since 1992)  
3190 S. Wadsworth Blvd., #250  
Lakewood, CO 80227

Education: Gettysburg College, Gettysburg, Pennsylvania, Biology, A.B., 1965.  
The George Washington University School of Medicine,  
Neuroanatomy, M.S.  
The George Washington University School of Medicine, (GWU);  
M.D., (with Honors)), 1970.

Post-Doctoral  
Training: University of Rochester School of Medicine, Strong Memorial  
Hospital, Rochester, New York, Medicine Internship, 1970-71.  
University of Rochester School of Medicine, Strong Memorial  
Hospital, Rochester, New York, Assistant Medical Resident,  
1971-72.  
University of Rochester School of Medicine, Strong Memorial  
Hospital, Rochester, New York, Associate Medical Resident,  
1972-73.  
University of Rochester School of Medicine, Strong Memorial Hospital,  
Rochester, New York, Chief Medical Resident, 1973-74.  
University of Colorado Medical Center, Denver, Colorado, Clinical  
Fellow in the Division of Renal Diseases, 1974-75.  
University of Colorado Medical Center, Denver, Colorado, Research  
Fellow in the Division of Renal Diseases, 1975-76.

Academic  
Appointments: University of Colorado Medical Center, Denver, Colorado, Instructor in  
Medicine, 1975-76.  
University of Colorado Medical Center, Denver, Colorado, Assistant  
Professor of Medicine, 1975-77.

University of Colorado Medical Center, Denver, Colorado, Assistant  
Clinical Professor of Medicine, 1977-82.  
University of Colorado Medical Center, Denver, Colorado, Associate  
Clinical Professor of Medicine 1982-90.  
University of Colorado Medical Center, Denver, Colorado, Clinical  
Professor of Medicine, 1990-2005  
University of Colorado Medical Center, Denver, Colorado,  
Distinguished Clinical Professor of Medicine, 2006-Present

Licensure: Colorado, #18842

Board Certified: American Board of Internal Medicine, 1973.  
American Board of Nephrology, 1976.

Membership: Alpha Omega Alpha  
Fellow of American College of Physicians  
American Society of Nephrology  
American Society for Bone and Mineral Research  
Metabolic Bone Disease Society of Colorado  
American Federation for Clinical Research  
American Medical Association  
William Beaumont Research Society (GWU)  
Smith-Reed-Russell Medical Honor Society (GWU)  
Colorado Medical Society  
Clear Creek Valley Medical Society  
National Osteoporosis Society  
National Osteoporosis Foundation  
International Society for Clinical Densitometry  
International Committee for Standards in Bone Densitometry  
American Associate of Clinical Endocrinologists  
International Bone and Mineral Society  
International Osteoporosis Foundation  
National Bone Health Alliance

Honors and Awards:

Student Awards: Dodek Prize in Steroid Biochemistry. (1st in Biochemistry: GWU )  
Perry Prize in Pathology. (1st in Pathology: GWU)

Upjohn Achievement Award for Outstanding Academic Attainment.  
(GWU)

First Prize, The William Beaumont Medical Research Society, 1968.  
(GWU)

Third Prize, University of Texas National Research Forum,  
Galveston, Texas, 1968.

Post-Doctoral Awards: Honorary Doctor of Science, Gettysburg College, Gettysburg, Pa 1997  
Distinguished Alumni Award, Gettysburg College, 1993  
Distinguished Alumni Award, George Washington University ,  
Washington, D.C. 2012

Outstanding Teacher of the Year Award, Department of Medicine,  
University of Colorado School of Medicine, 1980-81.  
Outstanding Clinical Faculty Research Award, Department of  
Medicine, University of Colorado School of Medicine, 1991.  
Outstanding Clinical Faculty Academic Publications Award, University  
of Colorado School of Medicine, 1995  
Outstanding Volunteer Faculty, Denver Health and Hospitals, 1998  
Outstanding Clinical Faculty Academic Publications Award, University  
of Colorado Health Sciences Center, 2000  
Career Achievement Award, Dept. Medicine, University of Colorado  
Health Sciences Center, 2005  
Distinguished Clinical Professor of Medicine, Dept of Medicine,  
University of Colorado School of Medicine, 2008-current

Professional Activities: By date:

Program Chairman, Annual Meeting, The Colorado Chapter,  
American College of Physicians, Colorado Springs, Colorado,  
January 1986.

Founder and Program Chairman, Adult Clinical Working Group,  
American Society for Bone and Mineral Research, Anaheim,  
California, June 1986; Indianapolis, Indiana, June 1987; New  
Orleans, Louisiana, June 1988.

Founder: Metabolic Bone Disease Society of Colorado, 1984;  
President 1992-present.

Board Member and Advisor, Osteoporosis Prevention Program,  
Colorado Department of Health, 1991-2001.

National Osteoporosis Foundation, Research Grant Committee of the  
Scientific Advisory Board, 1993-present

American Society for Bone and Mineral Research, Professional  
Practice Committee, 1995-2002; Publications Committee 2011-  
current.

National Osteoporosis Foundation, *Osteoporosis: Clinical Updates  
Newsletter*, Editorial Board, 1995-present

Chairman, Steering Committee, Society for Clinical Densitometry,  
1992-1996.

Founding President, International Society for Clinical Densitometry,  
1996-1999.

Interspecialty Council, National Osteoporosis Foundation, 1999-2004

Committee of Scientific Advisors, International Osteoporosis Foundation, 2000-present

Board of Directors, International Osteoporosis Foundation 1996-2011

ISCD representative to the NBHA Steering committee to Enhance Research, Surveillance & Evaluation- 2011-current

Editorial Board, *Osteoporosis: Index & Reviews*, 1995-present

Editorial Board, *Journal of Women's Health*, 1998-present

Editorial Board, *Calcified Tissue International*, 2000-present

Editorial Board, *Current Osteoporosis Reviews*, 2003-present

Editorial Board, *Menopause Management*, 2003-present

Editorial Board-Osteoporosis International 2005-present

Associate Editor-Primer on the Metabolic Bone Disorders and Disorders of Mineral Metabolism American Society of Bone and Mineral Research 2008-current.

Editorial Board, *Journal of Clinical Densitometry*, 1998-2003

Editor-in-Chief, *Journal of Clinical Densitometry*, 2003-2011

Emeritus Editor-in-Chief, *Journal of Clinical Densitometry*, 2012-current

#### Research Grants

##### Awarded:

Washington Heart Association Research Grant, 1965-66.

National Kidney Foundation Research and Fellowship Grant, 1974-75.

NIH Post-Doctoral Fellowship, 1976-78.

Rocky Mountain Kidney Foundation Research Grant, 1976-77.

NIH Young Investigator Award, 1977.

#### Publications/Articles

1. **Miller PD**, Telford IR, Haas GR: Effect of hyperbaric oxygen on cardiogenesis in the rat. Biol Neonate 1971, 17:44-52.
2. **Miller PD**, Waterhouse C, Owens R, Cohen E: The effect of potassium-loading on sodium excretion and renin activity in Addisonian man. J Clin Invest 1975, 56:346.

3. **Miller PD**, Schrier RW: When ions, not edema, dictate diuretics. Drug Therapy 1976, 6:141-153.
4. Cronin RE, Kaehny WD, **Miller PD**, Stables D, Gabow PA, Ostroy PR, Schrier RW: Renal cell carcinoma: Unusual systemic manifestations. Medicine 1976, 55:291-311.
5. McDonald KM, **Miller PD**, Anderson RJ, Berl T, Schrier RW: Hormonal control of renal water excretion. Kid Int 1976, 10:38-45.
6. Henrich WL, Cronin RE, **Miller PD**, Anderson RJ: Hypotensive sequelae of diazoxide and hydralazine. JAMA 1977, 237:246-265.
7. **Miller PD**, Heinig RE, Waterhouse C: Treatment of alcoholic acidosis. Arch Int Med 1978, 138:67-72.
8. **Miller PD**, Dubovsky SL, McDonald KM, Arnaud C, Schrier RW: Hypocalciuric effect of lithium in man. Min and Elect Metabolism 1978, 1:3-11.
9. Cronin RE, deTorrente A, **Miller PD**, Bulger RE, Schrier RW: Pathogenic mechanisms in early norepinephrine-induced acute renal failure: Functional and histological correlates of protection. Kid Int 1978, 14:115-125.
10. **Miller PD**, Berns AS: Acute metabolic alkalosis perpetrating hypercarbia: A role for acetazolamide in COPD. JAMA 1977, 238:2400-2401.
11. Goodman M, Solomons C, **Miller PD**: Distinction between the common symptoms of the phosphate-depletion syndrome and glucocorticoid-induced disease. Am J Med 1978, 65(5):868-872.
12. Heinig RE, **Miller PD**, Waterhouse C: Lactic Acidosis and Liver Disease. Arch Int Med 1979, 139:1229-1232.
13. Linas SL, **Miller PD**, McDonald KM, Stables OP, Katz F, Weil R, Schrier RW: Role of the renin angiotensin system in post-transplantation hypertension in patients with multiple kidney. NEJM 1978, 89:1440-1444.
14. deTorrente A, **Miller PD**, Cronin RE, Paulsen PE, Erickson AL, Schrier RW: Effects of furosemide and acetylcholine in norepinephrine-induced acute renal failure. Am J Physiol 1978, 235:131-136.
15. **Miller PD**, Krebs RA, Neal BJ, McIntyre DO: Hypomagnesemia suppression of the secondary hyperparathyroidism of chronic renal failure. JAMA 1979, 241:722-723.
16. **Miller PD**, Dubovsky SL, McDonald KM, Katz FH, Robertson GL, Schrier RW: Central

- adrenal and renal effects of lithium in man. Am J Med 1979, 66:797-803.
17. Anderson RJ, **Miller PD**: Mechanism of hypertension in nonazotemic patients with polycystic kidney disease. Min and Elec Metabolism 1979, 2:137-141.
  18. **Miller PD**, Linas SL, Anderson RJ, McDonald KM, Schrier RW: Nephrotoxic and natriuretic effects of demeclocholore-tetracycline (DMC) in hyponatremic cirrhotic subject (HBS). JAMA 1980, 243:2513-2514.
  19. **Miller PD**, Krebs RA, Neal BJ, McIntyre DO: Polyuric prerenal failure. Arch Int Med 1980, 140:907.
  20. Krebs RA, Fisher L, Neal BJ, McIntyre DO, **Miller PD**: Actinobacillus actinomycetemcomitans endocarditis with Henoch-Schonlein's purpura. Rcky Mtn Med J 1981, 78:23-27.
  21. Szatalowicz VL, **Miller PD**, Lacher JL, Gordon JA, Schrier RW: Comparative effect of diuretics on renal water excretion in hyponatremic oedematous disorders. Clin Sci 1982, 62(2):235-238.
  22. **Miller PD**, Krebs RA, Neal BJ, McIntyre DO: Hypodypsia in the geriatric patient. Am J Med 1982, 73:353-356.
  23. **Miller PD**, Huffer W, Krebs RA, Neal BJ, McIntyre DO: Osteomalacia in adults: The value of bone histology in evaluating osteopenia. Clin Res 1982, 30:400.
  24. Miller PD: Prevention and treatment strategies for reducing incidence of osteoporotic fractures in older patients. Ger Med Today 1988, 7:23-29.
  25. **Miller PD**: Diagnosis and treatment of osteoporosis. Int Med for the Specialist 1988, 9:67-80.
  26. **Miller PD**: Osteoporosis - recent developments in diagnosis and treatment. The Female Patient 1990, 15:49-61.
  27. Watts NB, Harris ST, Genant HK, Wasnich RD, **Miller PD**, et.al.: Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990, 323:73-79.
  28. Watts NB, Chesnut C, Heaney R, **Miller P**: Osteoporosis - its prevention, diagnosis and treatment. Med Times 1990, 118:39-45.
  29. **Miller PD**: Osteoporosis - new developments in prevention and treatment. Physician Assistant 1990, 14:17-28.
  30. Grimston SK, Sanborn CF, **Miller PD**, Huffer WE: Application of historical data for evaluation of osteopenia in female runners: The menstrual index. Clin Sports Med 1990,

2:108-118.

31. **Miller PD**, Neal BJ, McIntyre DO: The effect of cyclical phosphorus-etidronate therapy (ADFR) on axial bone mass in postmenopausal osteoporosis. Osteoporosis Int 1991, 1:171-176.
32. Watts NB, Genant HK, Harris ST, Jackson RD, Licata AA, **Miller PD**, Wasnich RD, Chesnut CH III: Clinical correlates of radiographic apparent vertebral fractures. Calcified Tissue Int 1991, 48(Supple):39-40.
33. **Miller PD**: The diagnosis and treatment of osteoporosis in primary care practice. Modern Med, January, 1992.
34. Ross PD, Genant HK, Davis JW, **Miller PD**, Wasnich RD: Predicting vertebral fracture incidence from prevalent fractures and bone density among non-black, osteoporotic women. Osteoporosis Int 1993, 3:120-126.
35. Licata AA, Chesnut CH III, Genant HK, Harris ST, Jackson RD, **Miller PD**, Ross PD, Wasnich RD, Watts NB: Effects of 5 years follow-up cyclical etidronate treatment in postmenopausal osteoporotic women. J Bone Mineral Res, 1993, 8(S1):S141.
36. **Miller PD**, Hamilos DL, McIntyre DO, Yanover MJ, Anger MS, Harrison MN, Gillum DM, Fish EM, Erickson AL. Cyclical etidronate increases bone mass in patients with established steroid-induced osteoporosis. J Bone Mineral Res, 1993, 8(S1):S338.
37. Harris ST, Jackson RD, Genant HK, Watts NB, Licata AA, Wasnich RD, **Miller PD**, Chesnut CH III: Cyclical etidronate treatment of postmenopausal osteoporosis - 4 year experience. Am J Med 1993, 95:557-567.
38. Conroy BP, Kraemer WJ, Dalsky GP, **Miller PD**, Fleck SJ, Kearney JT, Stone MH, Warren B, Maresh CM: Bone mineral density in elite junior weightlifters. Med and Science in Sports and Exercise, 1993, 25:1103-1109.
39. Ott SM, Woodson GC, Huffer WE, **Miller PD**, Watts NB: Bone histomorphometric changes following cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis. J Clin Endocrin Metab 1994, 78:968-972.
40. **Miller PD**. Osteoporosis Awareness in 1994. Colorado Medicine 1994, Nov:398-400.
41. **Miller PD**. Bone densitometry and osteoporotic fracture risk. Letter to the Editor. Am Family Phys 1994, 50:922-924.
42. Panigrahi K, Delmas PD, Singer F, Ryan W, Reiss O, Fisher R, **Miller PD**, Misrahi I, Darte C, Kress BC. Characteristics of a two-site immunoradiometric assay for measuring human skeletal alkaline phosphatase in serum. Clin Chem 1994, 40:822-828.

43. **Miller PD.** Exercise and bones: A hard (or soft) choice. Birch Scroll March 1995:24.
44. **Miller PD.** Cyclical etidronate for the treatment of postmenopausal osteoporosis. Osteoporosis Japan 1995, 3:22-28.
45. **Miller PD,** Rosen C, Bonnick S. Guidelines for the clinical utilization of bone mass measurement in the adult population. Calcif Tissue Int 1995, 57:251-252.
46. **Miller PD,** Harper KD. The World Health Organization criteria for the diagnosis of osteoporosis should be endorsed, Pro and Con. Osteoporosis: Index & Reviews 1995, 1:3,18,19.
47. **Miller PD:** Critical drug appraisal: Etidronate intermittent cyclic therapy for postmenopausal osteoporosis. Br J Clin Practice 1996, 50:23-31.
48. **Miller PD,** Bonnick SL, Rosen CJ. Clinical utility of bone mass measurements in adults: Consensus of an international panel. Sem in Arthritis Rheum 1996, 25:361-372.
49. Ettinger B, **Miller P,** McClung M. Use of bone densitometry results for decisions about therapy for osteoporosis. Letter. Ann Intern Med 1996, 125:623.
50. **Miller PD,** McClung M. Prediction of fracture risk I: Bone density. Am J Med Sci 1996, 312:257-259.
51. **Miller PD.** Parathyroid dysfunction in renal disease. Curr Op in Endocrin Diabetes 1996, 3:529-531.
52. **Miller PD.** The interpretation of bone mineral density: Clues to misdiagnosis. Osteoporosis: Index & Reviews 1996, 2:8-9.
53. **Miller PD,** Bonnick SL, Rosen CJ. Consensus of an international panel on the clinical utility of bone mass measurements in the detection of low bone mass in the adult population. Calcif Tissue Int. 1996; 58:207-214.
54. Epstein S, **Miller PD.** Bone mass measurement: The case for selected screening. Trends in Endo Metab, 1997, 8:157-160.
55. Gluer C-C for the International Quantitative Ultrasound Consensus Group. Quantitative ultrasound techniques for the assessment of osteoporosis: Expert agreement on current status. J Bone Miner Res 1997, 12:1280-1288.
56. Baran DT, Faulkner KG, Genant HK, **Miller PD,** Pacifici R. Diagnosis and management of osteoporosis: Guidelines for the utilization of bone densitometry. Calcif Tissue Int 1997;61:433-440.



57. Osteoporosis Quality of Life Study Group. Measuring quality of life in women with osteoporosis. Osteoporosis Int 1997;7:478-487.
58. International Committee for Standards in Bone Measurement. Letter to the Editor: Standardization of Femur BMD. J Bone Miner Res 1997;12:1316-1317.
59. **Miller PD**, Watts NB, Licata AA, Harris ST, Genant HK, Wasnich RD, Ross PD, Jackson RD, Hoseyni MS, Schoenfeld SL, Valent DJ, Chesnut CH III. Cyclical etidronate in the treatment of postmenopausal osteoporosis: Efficacy and safety after seven years of treatment. Am J Med 1997; 103:468-476.
60. **Miller PD**. Expanding the list of etiologic factors for osteoporosis in men. Endocrin Prac 1997; 3:261-263.
61. Siris E, **Miller P**, Barrett-Connor E, Abbott T, Sherwood L, Berger M. Design of NORA, the National Osteoporosis Risk Assessment Program: A longitudinal US registry of postmenopausal women. Osteoporosis Int 1998; S1:S62-S69.
62. **Miller PD**. Efficacy and safety of cyclical etidronate therapy in the long-term treatment of osteoporosis. Rev Contemp Pharmacother 1998; 9:255-260.
63. **Miller P**, Lukert B, Broy S, Civitelli R, Fleischmann R, Gagel R, Khosla K, Lucas M, Maricic M, Pacifici R, Recker R, Sarran HS, Short B, Short MJ. Management of postmenopausal osteoporosis for primary care. Menopause 1998; 5:123-131.
64. **Miller PD**, Bonnick SL, Johnston CC Jr, Kleerekoper M, Lindsay RL, Sherwood LM, Siris ES. The challenges of peripheral bone density testing. Which patients need additional central density skeletal measurements? J Clin Densitom 1998; 1:211-217.
65. **Miller PD**. The use of risedronate in Paget's disease. Bone 1999; 24(S1):91S-92S.
66. **Miller PD**, Brown JP, Siris ES, Hoseyni MS, Axelrod DW, Bekker PJ. A randomized, double-blind comparison of risedronate versus etidronate in the treatment of Paget's disease of bone. Am J Med 1999; 106:513-520.
67. Bonnick SL, Faulkner KG, **Miller PD** for the Board of Trustees, ISCD. Qualifications for densitometry technologists. J Clin Densitom, 1999; 2:179-180.
68. **Miller PD**, Zapalowski C, Kulak CAM, Bilezikian JP. Bone densitometry: The best way to detect osteoporosis and to monitor therapy. J Clin Endocrin Metab, 1999; 84:1867-1871.
69. Cook DJ, Guyatt GH, Adachi JD, Epstein RS, Juniper EF; Protocol development; Austin PA, Clifton J, Adachi JD, Rosen CJ, Kessenich CR, Stock JL, Overdorf J, **Miller PD**, Erickson AL, McClung MR, McClung BL,; Data analysis; Griffith LE, Guyatt GH, Cook DJ; Manuscript preparation; Ioannidis G, Adachi JD, Guyatt GH. Development and validation of the mini-osteoporosis quality of life questionnaire (OQLQ) in osteoporotic women with back

- pain due to vertebral fractures. Osteoporosis Quality of Life Study Group. Osteoporos Int, 1999; 10:207-213.
70. **Miller PD**, Baran DT, Bilezikian JP, Greenspan SL, Lindsay R, Riggs BL, Watts NB. Practical clinical application of biochemical markers of bone turnover. J Clin Densitom 1999; 2:323-342.
  71. Faulkner KG, von Stetten E, **Miller P**. Discordance in patient classification using T-scores. J Clin Densitom 1999; 2:343-350.
  72. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseney MS, Axelrod DW, **Miller PD**. The effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis: A double-blind, randomized, placebo-controlled trial. JAMA 1999; 282:1344-1352.
  73. Genant HK,...**Miller PD**. Interim report and recommendations of the World Health Organization task-force for osteoporosis. Osteoporosis Int 1999; 10:259-264.
  74. Watts NB, **Miller PD**. Changing perceptions in osteoporosis. Markers should be used as adjunct to bone densitometry. BMJ 1999; 319(7221):1371-1372.
  75. **Miller PD**. Clinical application of bone density. J Florida MA, 2000; 86:11-17.
  76. Wasnich RD, **Miller PD**. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endo Metabolism 2000; 85:1-6.
  77. **Miller PD**. Controversies in bone mineral density diagnostic classification. Calcif Tissue Int 2000; 66:317-319.
  78. Kanis JA, Gluer C-C, for the Committee of Scientific Advisors, International Osteoporosis Foundation. An update on the diagnosis and assessment of osteoporosis with densitometry. Osteoporosis Int 2000; 11:92-202.
  79. **Miller PD**, Woodson G, Licata A, Ettinger M, Mako B, Smith M, Wang L, Yates J, Melton M, Palmisano J. Rechallenge of patients who discontinued alendronate therapy because of upper gastrointestinal symptoms. Clin Therap, 2000; 22:1433-1443.
  80. Greenspan S, Harris S, Bone H, **Miller P**, Orwoll E, Watts N, Rosen C. Bisphosphonates: Safety and efficacy in the treatment and prevention of osteoporosis. Am Family Prac, 2000; 61:2731-2736.
  81. Ettinger M, **Miller PD**, Notelovitz M. Bone mineral density testing: Who, when, how. Patient Care, 2000; 35:62-81.
  82. **Miller PD**. The treatment of osteoporosis: Antiresorptive therapy. Clin Lab Med 2000;

20:603-622.

83. Chesnut CH III, Silverman SL, Andriano K, Ettinger B, Genant HK, Gimona A, Harris S, Kiel DP, LeBoff M, Maricic MJ, **Miller P**, Moniz C, Peacock M, Richardson P, Watts N, Baylink DJ for the PROOF study group. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent reoccurrence of osteoporotic fracture study. The PROOF study group. Am J Med, 2000; 109:267-276.
84. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J for the Committee of Scientific Advisors of the International Osteoporosis Foundation. A position paper on the use of biochemical markers of bone turnover in osteoporosis. Osteoporosis Int, 2000; 11(S6):S2-S17.
85. Orwoll E, Ettinger M, Weiss S, **Miller P**, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A. Alendronate for the treatment of osteoporosis in men. N Engl J Med, 2000; 343:604-610.
86. McClung MR, Geusens P, **Miller PD**, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster J-Y. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med, 2001; 344:333-340.
87. **Miller PD**. New possibilities for diagnosis and treatment of osteoporosis. Int J Fertil 2001; 46:215-221.
88. **Miller PD**. Current controversies in bone densitometry. Menopause Management 2001; May/June:22-32.
89. Greenspan SL, Cheng S, **Miller PD**, Orwoll ES for the QUS-2 PMA Trials Group. Clinical performance of a highly portable, scanning calcaneal ultrasonometer. Osteoporosis Int, 2001; 12:391-398.
90. Sarno M, Sarno L, Baylink D, Drinkwater B, Farley S, Kleerekoper M, Lang R, Lappe J, Licata A, McClung M, **Miller P**, Natrass S, Recker R, Schwartz EN, Singer F, Tucci JR, Wolf S, Powell H, Tjersland G, Warnick GR. Excretion of sweat and urine pyridinoline crosslinks in healthy controls and subjects with established metabolic bone disease. Clin Chem Lab Med, 2001; 39:223-228.
91. Bonnick SL, Johnston CC Jr, Kleerekoper M, Lindsay R, **Miller P**, Siris E. Importance of precision in bone density measurements. J Clin Densitom 2001; 4:105-110.
92. Siris E, **Miller P**, Barrett-Connor E, Faulkner K, Wehren L, Abbott T, Berger M, Santora A, Sherwood L. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: Results from the National Osteoporosis Risk Assessment (NORA). JAMA 2001; 286:2815-2822.
93. **Miller PD**. Bisphosphonates for the prevention and treatment of corticosteroid-induced

- osteoporosis. Osteoporos Int 2001; 12(S3):S3-S10.
94. Adachi JD, Adami S, **Miller PD**, Olszynski WP, Kendler DL, Silverman SL, Licata AA, Li Z, Gomez-Panzani E. Tolerability of risedronate in postmenopausal women intolerant of alendronate. Aging Clin Exp Res 2001; 13:347-354.
  95. Greenspan SL, Schneider DL, McClung MR, **Miller PD**, Schnitzer TJ, Bonin R, Smith ME, DeLucca P, Gormley GJ, Melton ME. Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. Ann Intern Med 2002; 136:742-746.
  96. Hochberg M, Greenspan S, Wasnich R, **Miller P**, Thompson D, Ross P. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002; 87:1586-1592.
  97. **Miller PD**, Njeh C, Jankowski LG, Lenchik L. What are the standards by which bone mass measurement at peripheral skeletal sites should be used in the diagnosis of osteoporosis? J Clin Densitom 2002; 5(S1):S39-S45.
  98. Khan AA, Brown J, Faulkner K, Kendler D, Lentle B, Leslie W, **Miller PD**, Nicholson L, Olszynski WP, Watts NB. Standards and guidelines for performing central dual x-ray densitometry from the Canadian panel of International Society for Clinical Densitometry. J Clin Densitom 2002; 5:435-445.
  99. Khan AA, Brown JP, Kendler DL, Leslie WD, Lentle BC, Lewiecki EM, **Miller PD**, Nicholson RL, Olszynski WP, Watts NB. The 2002 Canadian bone densitometry recommendations:take-home messages. CMAJ 2002; 167:1141-1145.
  100. Body J-J, Gaich GA, Scheele WH, Kulkarni, **Miller PD**, Peretz A, Dore RK, Correa-Rotter R, Papaioannou A, Cumming DC, Hodsman AB. A randomized double-blind trial to compare the efficacy of teriparatide (recombinant human parathyroid hormone (1-34) to alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002; 87:4528-4535.
  101. **Miller PD**. Is bone mineral density (BMD) measurement a sufficient and useful indicator of when to start osteoporosis treatment. Medicographia 2002; 24:343-344.
  102. **Miller P**, Siris E, Barrett-Connor E, Faulkner K, Abbott T, Berger M, Santora A, Sherwood L. Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: Evidence from the National Osteoporosis Risk Assessment (NORA) program. J Bone Miner Res 2002; 17:2222-2230.
  103. **Miller PD**, Bilezikian JP. Bone densitometry in asymptomatic hyperparathyroidism. J Bone Miner Res 2002; 17(S2):N98-N102.
  104. Lenchik L, Leib ES, Hamdy RC, Binkley NC, **Miller PD**, Watts NB. Executive summary

International Society for Clinical Densitometry position development conference Denver, Colorado July 20-22, 2001. J Clin Densitom 2002; 5(S1):S1-3.

105. **Miller PD**. Editorial: Greater risk, greater benefit-True or False? J Clin Endocrinol Metab 2003; 88:538-541.
106. **Miller PD**. Review Article: Analysis of 1-year vertebral fracture risk reduction data in treatments for osteoporosis. Southern Medical Journal 2003; 96:478-485.
107. Siris ES, Chen Y-T, Weiss TW, Brenneman SK, **Miller PD**. National Osteoporosis Foundation Guidelines with peripheral BMD predict fractures in postmenopausal women. Drug Benefit Trends 2003; July:36-42.
108. Lenchik L, Leib ES, Hamby RC, Binkley NC, **Miller PD**, Watts NB. Position Development Conference. South Med J 2003; 96:724-725.
109. Kiebzak GM, **Miller PD**. Determinants of bone strength. J Bone Miner Res 2003; 18:383-384.
110. Barrett-Connor E, Wehren L, Siris E, **Miller PD**, Chen YT, Abbott T, Berger M, Santora A, Sherwood L. Recency and duration of postmenopausal hormone therapy: Effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study. Menopause 2003; 10:412-419.
111. Rosen CJ, Hochberg M, Bonnick S, McClung MR, **Miller PD**, Broy S, et al. Treatment with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: A randomized, double-blind study. J Bone Miner Res, 2005; 20:141-151.
112. **Miller PD**. Defining strategies for improving the identification and management of osteoporosis in the primary care setting. Int J Fertil 2003; 48; 25-31.
113. **Miller PD**. Review: Efficacy and safety of long-term bisphosphonates in postmenopausal osteoporosis. Expert Opin Pharmacother 2003; 4(12):2253-2258.
114. **Miller PD**. Review: Bone mineral density-clinical use and application. Endocrinol Metab Clin North Am 2003; 32(1):159-179.
115. **Miller PD**. Review: Bone mass measurements. Clin Geriatr Med 2003; 19(2):281-297.
116. Yates J, Barrett-Connor E, Barlas S, Chen Y-T, **Miller PD**, Siris ES. Rapid loss of hip fracture protection after estrogen cessation: Evidence from the National Osteoporosis Risk Assessment. Obstet Gynecol 2004; 103:440-446.
117. **Miller PD**, Bilezikian JP, Deal C, Harris ST, Pacifici R. Clinical use of teriparatide in the real world: Initial insights. Endo Prac 2004; 10:139-148.

118. Olszynski WP, Davison KS, Adachi JD, Brown JP, Cummings SR, Hanley DA, Harris ST, Hodzman AB, Kendler D, McClung MR, **Miller PD**, Yuen CK. Review: Osteoporosis in men: Epidemiology, diagnosis, prevention and treatment. Clin Therap 2004; 26:15-28.
119. **Miller PD**, Barlas S, Brenneman SK, Abbott TA, Chen Y-T, Barrett-Connor E, Siris ES. An approach to identifying osteopenic women at increased short-term risk of fracture. Arch Intern Med 2004; 164:1113-1120.
120. Siris ES, Chen Y-T, Abbott TA, Barrett-Connor E, **Miller PD**, Wehren L, Berger ML. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 2004; 164:1108-1112.
121. **Miller PD**. Pitfalls in bone mineral density measurements. Current Osteoporosis Reports 2004; 2:59-64.
122. Miller PD, Schnitzer T, Emkey R, Orwoll E, Rosen C, Ettinger M, Vandormael K, Daifotis A. Weekly oral alendronic acid in male osteoporosis. Clin Drug Invest 2004; 24:333-341.
123. **Miller PD**. Combination therapy for osteoporosis: parathyroid hormone and bisphosphonates. Curr Opin Orthop 2004; 15:389-395.
124. Khan AA, Bachrach L, Brown JP, Hanley DA, Josse RG, Kendler DL, Leib ES, Lentle BC, Leslie WD, Lewiecki EM, **Miller PD**, et al. Review: Standards and guidelines for performing central dual-energy x-ray absorptiometry in premenopausal women, men, and children. J Clin Densitom 2004; 7(1):51-64.
125. Siris ES, Brenneman SK, **Miller PD**, Barrett-Connor E, Chen YT, Sherwood LM, Abbott TA. Predictive value of low BMD for 1-year fracture outcomes is similar for postmenopausal women ages 50-64 and 65 and older: Results from the National Osteoporosis Risk Assessment (NORA). J Bone Miner Res 2004; 19(8):1215-1220.
126. **Miller PD**, Barlas S, Brenneman SK, Abbott TA, Chen YT, Barrett-Connor E, Siris ES. An approach to identifying osteopenic women at increased short-term risk of fracture. Obstet Gynecol Surv 2004; 59(1):768.
127. Siris ES, Chen YT, Abbott TA, Barrett-Connor E, **Miller PD**, Wehen LE, Berger ML. Bone mineral density threshold for pharmacologic intervention to prevent fractures. Obstet Gynecol Surv 2004; 59(1):769-771.
128. Hochberg MC, **Miller PD**, Wasnich RD, Ross PD, Greenspan S. Letter to the editor. Bone 2004; 35(5):1222-1224.
129. Rosen CJ, Hochberg M, Bonnicksen S, McClung MR, **Miller PD**, Broy S, et al. Treatment with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: A randomized, double-blind study. J Bone Miner Res, 2005;

20:141-151.

130. Binkley N, Kiebzak GM, Lewiecki EM, Krueger D, Gangnon RE, **Miller PD**, Shepherd JA, Drezner MK. Recalculation of the NHANES database SD improves T-score agreement and reduces osteoporosis prevalence. J Bone Miner Res, 2005; 20:195-201.
131. Barrett-Connor E, Siris ES, Wehren LE, **Miller PD**, Abbott TA, Berger ML, Santora AC, Sherwood LM. Osteoporosis and fracture risk in women of different ethnic groups. J Bone Miner Res, 2005;20:185-194.
132. **Miller PD**. Treatment of osteoporosis in chronic kidney disease and end-stage renal disease. Current Osteoporosis Reports, 2005; 3:5-12.
133. Cryer B, **Miller PD**, Petruschke RA, Chen E, Geba GP, DePapp AE. Upper gastrointestinal tolerability of one weekly alendronate 70 mg with concomitant non-steroidal anti-inflammatory drug use. Aliment Pharmacol Ther 2005; 21:599-607.
134. Hodsman AB, Bauer DC, Dempster D, Dian L, Hanley DA, Harris ST, Kendler D, McClung MR, **Miller PD**, Olszynski WP, Orwoll E, Yuen CK. Parathyroid hormone and teriparatide for the treatment of osteoporosis: A review of the evidence and suggested guidelines for its use. Endocrine Reviews 2005; 10:2004-2006.
135. **Miller PD**. Treatment of metabolic bone disease in patients with chronic renal disease: A perspective for rheumatologists. Current Rheumatology Reports, 2005, in press
136. **Miller PD**, Shergy WJ, Body J-J, Chen P, Rohe ME, Krege JH. Long-term reduction in back pain risk in women having osteoporosis treated with teriparatide compared with alendronate. J Rheumatology, 2005, in press.
137. **Miller PD**, McClung M, Macovei L, Stakkestad J, Luckey M, Bonvoisin B, Reginster J-Y, Recker R, Hughes C, Lewiecki M, Felsenberg D, Delmas P, Kendler D, Bolognese M, Mairon N, Cooper C. Monthly oral ibandronate therapy in postmenopausal osteoporosis: One year results from the MOBILE study. J Bone Miner Res, 2005, in press.
138. **Miller PD**, Hochberg MC, Wehren LE, Ross PD, Wasnich RD. How useful are measures of BMD and bone turnover? Curr Med Res Opin, 2005; 21 (4): 545-553.
139. McClung M, San Martin J, **Miller PD** et al: Teriparatide and Alendronate Increase Bone Mass by Opposite Effects on Bone Remodeling. Arch Int Med 2005; 165: 1762-1768.
140. **Miller PD**. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy. Clinical Therapeutics 2005; 27 (4): 1-16.
141. Chesnut CH, Ettinger MP, **Miller PD**, Baylink D, Emkey R, Harris ST, Wasnich RD,

Watts NB, Schimmer RC, and Recker RR. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. *Current Medical Research Opinion* 2005; 21 (3): 391-401.

142. Lewiecki EM, **Miller PD**, Leib ES and Bilezikian JP. The perspective of the International Osteoporosis Foundation on the official positions of The International Society for Clinical Densitometry. *Osteoporosis Internat* 2005; 16: (5): 579.
143. Lewiecki EM, **Miller PD**, Leib ES, and Bilezikian JP. Response to “The Perspective of The International Osteoporosis Foundation on the Official Positions of the International Society for Clinical Densitometry by John A Kanis et al. *J Clin Densit.*2005 8(2): 143-144.
144. Reid IR, **Miller PD**, Lyles K, Brown J, Fraser B, Hosking D, Youssef S, Mesenbrink P, Richardson P. A single infusion of Zoledronic acid improves remission rates in Paget’s Disease: A randomized controlled comparison with risedronate *New Engl J Med* 2005; 353 (9): 22-32.
145. Ettinger MP, Felsenberg D, Harris ST, Wasnich R, Skag A, Hiltbrunner V, Wilson K, Schimmer, and **Miller PD**. The safety and tolerability of oral daily and intermittent ibandronate are not influenced by age. *J Rheum* 2005 (in press).
146. **Miller PD**. Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction. *Current Osteoporosis Reports.* 2005; 3 (3): 103-110.
147. Siris E, Brenneman SK, Barrett-Conner E, **Miller PD**, Sajjan S, Berger ML, and Chen YT. The effect of age and bone mineral density on the absolute, excess and relative risk of fracture in postmenopausal women: age 50-99: Results from the National Osteoporosis Risk Assessment. *Osteoporosis Internatl* 2006; 17 (4): 565-574.
148. **Miller PD**, Roux C, Boonen S, Barton I, Dunlap L , and Burgio D. Safety and Efficacy of Risedronate in Patients with Age-Related Reduced Renal Function as Estimated by the Cockcroft and Gault Method: A Pooled Analysis of Nine Clinical Trials. *J Bone Miner Res* 2005 20: (12): 2015-2115.
149. Felsenberg D, **Miller PD**, Armbrecht G, Wilson K, Schimmer RC, and Papapoulos SE. Oral bandronate significantly reduces the risk of vertebral fractures of greater severity after 1,2 and 3 years in postmenopausal women with osteoporosis. *BONE* 2005; 37: 651-654.
150. Kaunitz A, **Miller PD**, McClung M et al. Bone mineral density in women aged 25-35 years receiving depo medroxyprogesterone acetate: recovery following discontinuation. *Contraception* 2005.
151. **Miller PD**. Diagnosis and treatment of osteoporosis or fragility fractures in patients with chronic kidney disease. *Osteoporosis Clinical Updates* 2005; 2: 1-12 (National Osteoporosis Foundation).



152. Krege JH, **Miller PD**, Lenchik L, Misurski DA and Chen P. New or worsening lumbar spine vertebral fractures increases lumbar spine bone mineral density and falsely suggest improved skeletal status. *J Clin Densit* 2005 (in press).
153. Reid I, **Miller PD**, and Hosking D. Paget's disease and bisphosphonates. *New Engl J Med* 2005; 353: 2626-2618 (letter).
154. **Miller PD**, Silverman S, Gold D, and Wagman R. Rationale, objective and design of the direct analysis of nonvertebral fracture in the community experience (DANCE) Study. *Osteoporosis Internat* 2006; 17 (1): 85-90.
155. *Miller PD*, Hochberg MC, Wehren LE, Ross P, and Wasnich RD. How useful are measures of BMD and bone turnover? *Clinical Medical Research Opinions*. 2005; 4: 545-554.
156. **Miller PD**, Silverman S, Gold DT, Taylor KA, Chen P, and Wagman RB. Rationale, objectives, and design of the Direct Analysis of Nonvertebral fracture in the Community Experience (DANCE) study. *Osteoporosis Internat* 2006; 85-90.
157. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, **Miller PD**, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, and Bekker PJ. Denosumab in postmenopausal women with low bone mass. *New Engl J Med* 2006; 354: 821-831.
158. Reginster JY, Felsenberg D, Cooper C, Stakkestad JA, **Miller PD**, Kendler DL, Adami S, McClung MR, Bolognese MA, Civitelli R, Dumont E, Bonvosism B, Recker RR, and Delmas PD. A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. *Osteoporosis Internat* 2006; 17 (2): 159-166.
159. Wagman R and **Miller PD**. The use of teriparatide and PTH (1-84) for the treatment of osteoporosis. *Clinical Reviews in Bone and Mineral Metabolism*. Ed. Dempster D. 2006; 4 (4): 1-13.
160. Lewiecki EM, **Miller PD**, McClung MR, Cohen SB, Bolognese MA, Lu Y, Wang A, Siddhanti S, Fitzpatrick LA, for the AMG 162 Bone Loss Study Group. Two-year treatment with Denosumab (AMG 162) of postmenopausal women with low bone mineral density in a randomized phase 2 study. *J Bone Miner Res* 2007; 22 (12): 1832-1841.
161. Siris ES, Brenneman SK, Barrett-Conner E, **Miller PD**, Sajjan S, Berger ML, Chen Y-T. The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50-99: results from the National Osteoporosis Risk Assessment (NORA). *Osteoporosis Internat* 2006; 17 (4): 565-574.
162. Krege JH, **Miller PD**, Lenchik L, Misurski DA, and Chen P. New or worsening lumbar spine vertebral fractures increase lumbar spine bone mineral density and falsely

suggest improved skeletal status. *J Clin Densit* 2006; 9 (2): 144-149.

163. Chen P, **Miller PD**, Delmas PD, Misurski DA, Krege JH. Change in lumbar spine bone mineral density and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. *J Bone Miner Res* 2006. 21: 1785-1790.
164. Lewiecki EM, Richmond B, **Miller PD**. Uses and misuse of quantitative ultrasonography in managing osteoporosis. *Cleveland Clinic Journal of Medicine*. 2006; 73 (8): 742-752.
165. **Miller PD**, Schwartz EN, Chen P, Misurski DA, Krege JH. Teriparatide in postmenopausal women with osteoporosis and impaired renal function. *Osteoporosis Internat*. 2007; 18:59-68.
166. Kebzack G, Binkley N, Lewiecki M, **Miller PD**. Diagnostic agreement at total hip using different DXA systems and the NHANES III database. 2007; *Osteoporosis Internat* (in press).
167. Hosking D, Lyle K, Brown JP, Fraser WD, **Miller PD**, Curiel MD, Devogelaer JP, Hooper H, Su G, Zelenakas K, Pak J, Fashola T, Saidi Y, Eriksen EF, Reid IR. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. *J Bone Miner Res* 2007; 22 (1): 142-148.
168. **Miller PD**. Guidelines for the diagnosis of osteoporosis: T-scores vs Fractures. *Rev Endocr Metab Disord* 2006; 7: 75-89.
169. **Miller PD**. Monitoring osteoporosis therapies. *Current Osteoporosis Reports* 2007; 5: 38-43.
170. Chen YT, **Miller PD**, Barrett-Conner E, Weiss TW, Sajjan SG, and Siris E. An approach for identifying postmenopausal women age 50-64 years at increased short term risk for osteoporotic fracture. *Osteoporosis Internat* 2007; 18: 1287-1296.
171. **Miller PD**. Is there a role for bisphosphonates in patients with stage 5 chronic kidney disease? *Seminars in Dialysis*. 2007; 20: 191-197.
172. Weiss T, Siris ES, Barrett-Conner E, *Miller PD*, McHorney C, and Teutsch S. Osteoporosis practice patterns in 2006 among primary care physicians participating in the NORA study. *Osteoporosis Internat* 2007 (in press).
173. **Miller PD**, Bilezikian JP, Diaz-Curiel M, Chen P, Marin F, Krege J, Wong M, Marcus R. Occurrence of hypercalciuria in patients treated with teriparatide. *J Clin Endo Metab* 2007; 92 (9): 3535-3541.
174. Lewiecki EM **and Miller PD**. Renal safety of intravenous bisphosphonates in the treatment of osteoporosis. *Exp Opinion in Drug Safety* 2007; 6(6): 1-10.

175. **Miller PD**, Christiansen C, Hoeck HC, Kendler DL, Lewiecki EM, Woodson G, Levine AB, Chines AA, Constantine G, Delmas PD. Effects of Bazedoxifene on Bone Mineral Density and Turnover in Postmenopausal Women: 2-Year Results of a Randomized, Double-Blind, Placebo- and Active-Controlled Study. *J Bone Miner Res* 2008;
177. **Miller PD**. Non-vertebral fracture risk reduction with oral bisphosphonates: challenges with interpreting clinical trial data. *Curr Med Res Opin* 2008; 24: 107-119.
178. Recker RR, Delmas PD, Halse J, Reid IR, Boonen S, Garcia P, Supronik J, Ochoa ML, **Miller PD**, Hu H, Mesenbrink P, Hartl F, Gasser J, Eriksen EF. The Effects of Zoledronic Acid 5 mg iv. Once Yearly on Bone Remodeling and Bone Structure *JBMR* 2007 (Online).
179. McClung MR, Recker RR, **Miller PD**, Fiske D, Minkoff J, Kriegman A, Zhou W, Adeera M, Davis J. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone mineral density previously treated with alendronate. *Bone* 2007; 41: 122-128.
180. Pazianas M, **Miller PD**, Blumenthal W, Berna M, and Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. *Clinical Therapeutics* 2007; 29 (8): 1-11.
181. Chen P, **Miller PD**, Recker RR, Resch H, Rana A, Pavo I, Sipos AA. Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis. *J Bone Miner Res*. 2007; 22: 1173- 1180.
182. Barrett-Conner E, Sajjan SG, Siris ES, **Miller PD**, Chen YT, Markson L. WRIST FRACTURE AS A PREDICTOR OF FUTURE FRACTURES IN YOUNGER VERSUS OLDER POSTMENOPAUSAL WOMEN: RESULTS FROM THE NATIONAL OSTEOPOROSIS RISK ASSESSMENT (NORA). *Osteoporosis Internat* 2008; 19: 607-613 .
183. Pazianas M, Blumenthal W, **Miller PD**. "Lack of Association between Oral Bisphosphonates and Osteonecrosis of the Jaw using Jaw Surgery as a Surrogate Marke. *Osteoporosis Internat* 2007 (in press).
184. Recker RR, Delmas PD, Halse J, Reid IR, Boonen S, Garcia-Hernandez PA, Sopronik J, Lewiecki EM, Ochoa L, **Miller PD**, Hu H, Mesenbrink P, Hartl F, Gasser J, Eriksen EF. The effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. *J Bone Miner Res*. 2007 (in press).
185. Barrett-Conner E, McHorney CA, **Miller PD**, Siris E. Predictors of estrogen discontinuation after the Women's Health Initiative: Results from the National Osteoporosis Risk Assessment (NORA). *Osteoporosis Internat* 2007 (in press).
186. Cranney A, Wells G, Yetsis L, Papapoulos S, Adami S, Delmas P, Cooper C, **Miller PD**, Reginster JY, Sambrook P, Silverman S, Siris E, Adachi R. A meta-analysis of individual patient data for the prevention of non-vertebral fractures with ibandronate. *Osteoporosis Internat* 2008 (in press)

187. **Miller PD**. Intravenous bisphosphonate safety: The Realities. *Bone* 2007; 41 (5): S42-S43.
188. Breanne J, Sherif K, Marcel S, Jinaglai J, Newell J, Hiromoto S, Marcel S, Yuyan S, Zhen W, Hochberg M, **Miller PD**, Melton J. Comparative effectiveness of treatments to prevent fractures on women and men with low bone density or osteoporosis: a systematic review. *Annals of Int Med* 2007 (in press).
189. Harris S, Blumenthal W, **Miller PD**. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a metaanalysis of phase III studies. *Current Medical Res Opinion* 2008; 24: 237-245.
190. Boonen S, Sellmeyer D, Lippuner K, Orlov-Morozov, Abrams K, Messenbrink P Eriksen EF and **Miller PD**. Renal safety of annual infusion of zoledronic acid in osteoporotic postmenopausal women. *Kidney Internat* 2008; : 1-8.
191. Shane E, Civitelli R, Delmas PD, Drezner M, Eisman J, Lindsay R, Lorenzo J, **Miller PD**, Ralston S, Reid I, and Siris E. Maintaining the trust of physicians and the public in the medical literature: report of a task force on scientific publishing of clinical trials. *J Bone Miner Res* 2007; 22(11): 1661-1667.
193. **Miller PD**, Delmas PD, Lindsay R, Watts NB, Luckey M, Adachi J, Saag K, Greenspan SL, Seeman E, Boones S, Meeves S, Lang TF, and Bilezikian JP. Clinical responsiveness of women with osteoporosis to teriparatide following therapy with alendronate or risedronate. *J Clin Endocrinol Metab* 2008 (in press).
194. Carey JJ, Delaney MF, Love TE, Richmond BJ, Cromer BA, **Miller PD**, Manilla-McIntosh M, Lewis SA, Thomas CL, and Licata AA. DXA-generated Z-scores and T-scores may differ substantially and significantly in young adults. *J Clin Densit* 2007; 10 (4): 351-358.
195. **Miller PD**, Epstein S, Sedarati F, Reginster JY. Once monthly oral ibandronate compared with weekly alendronate: results from the head-to-head MOTION study. *Current Medical Research Opinion* 2008; 24: 207-213.
196. **Miller PD**, Ward P, Pfister T, Leigh C, Body JJ. Renal tolerability of intermittent intravenous ibandronate treatment for patients with postmenopausal osteoporosis: a review. *Clinical and Experimental Rheumatology*. 2008 (in press).
197. **Miller PD**. Safety of parathyroid hormone for the treatment of osteoporosis. *Current Osteoporosis Reports* 2008; 6:12-16.
198. Chen P, Miller PD, Binkley NC, and Kendler DL. Use of lowest individual lumbar spine BMD T-score for diagnosis of osteoporosis and for prediction of prevalent and incident vertebral fractures. *J Clin Densit* 2008 (in press)
199. Beck TJ, Lewiecki EM, **Miller PD**, Felsenberg D, Liu Y, Ding B, Libanti C. Effects of Denosumab on the Structural Geometry of the Proximal Femur in Postmenopausal Women with Low Bone Mass *J Clin Densit* 2008; 11 (3):
200. **Miller PD**, Bolognese MA, Lewiecki EM, McClung MR, Beiying D, Austin M, Liu Y, San Martin J, for the AMG 162 Bone Loss Study Group. Long term efficacy and safety

of Denosumab treatment in postmenopausal women with low bone mass: 48 month results of a randomized phase II clinical trial. *Bone* 2008; 43(2): 222-229.

201. Fan B, Lewiecki EM, Genant HK, Lu Y, Sherman M, **Miller PD**, Shepherd J. Improved precision with Hologic Apex software. *Osteoporosis Internat* 2008 (in press).

202. Lewiecki EM, Bilezikian JP, Hochberg MC, Luckey MM, Maricic M, **Miller PD**. Proceedings of the Eighth Annual Santa Fe Bone Symposium, August 3-4, 2007. *J Clin Densitom.* 2008; 11(2): 313-324.

203. Kanis J et al. WHO Scientific Group Technical Report: Assessment of osteoporosis at the primary care level-report of a WHO scientific group. University of Sheffield, UK 2007; 1-287.

204. Lindsay RL, **Miller PD**, Pohl G, Glass EV, Chen P, Krege JH. Relationship between duration of teriparatide and clinical outcomes in postmenopausal women with osteoporosis. *Osteoporosis Internat.* 2009; 20:943-948.

205. McClung MR, Bolognese M, Seadrati , Recker RR, and **Miller PD**. Efficacy and safety of monthly oral ibandronate in prevention of postmenopausal bone loss. *Bone* 2008;

206. Watts NB, **Miller PD**, Kohlmeier L, Sebba A, Chen P, Wong M, Krohn K. Fracture reduction and loss of femoral neck bone mineral density with teriparatide treatment. *J Bone Miner Res* 2009; (in press).

207. Barrett-Conner E, Weiss TW, McHorney CA, **Miller PD** and Siris ES. Predictor of falls among postmenopausal women : Results from the National Osteoporosis Risk Assessment (NORA). *Osteoporosis Internat* 2009; 20(5): 715-722.

208. **Miller PD**. The role of bone biopsy in chronic renal failure. *Clin Journ Amer Soc Nephrol* 2008; 3(3): S140-S151.

209. McClung M, Recker R, **Miller PD**, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J. Intravenous zoledronic acid 5mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. *Nat Clin Pract Endocrinol Metab.* 2008; 4(1): 20-21.

210. Watts NB, Lewiecki EM, **Miller PD**, and Baim SB. National Osteoporosis Foundation 2008 Clinician's Guide to The Prevention and Treatment of Osteoporosis and The World Health Organizations Fracture Risk Assessment Tool (FRAX™): What they mean to the bone densitometrists and bone technologists. *J Clin Densit* 2008; 11(4):

211. **Miller PD**. Skeletal Health and Bone Strength: DXA and Beyond. Growth for The Journal of Clinical Densitometry. *J Clin Densit.* 2008; 11(2): 344-346.

212. Krieg MA, Barkman R, Gonelli S, Stuart A, Bauer DC, Del Rio Barquero L, Kaufmann JJ, Lorenc R, **Miller PD**, Olszynski WP, Poiana C, Schott AM, Lewiecki EM, Hans D.

- Quantitative ultrasound in the management of osteoporosis: the 2007 ISCD Official Positions. *J Clin Densit* 2008 11(1): 163-187.
213. **Miller PD**. Anti-resorptives in the management of osteoporosis. *Best Practice and Research Clinical Endocrinology and Metabolism* 2008; 22 (5): 849-868.
  214. **Miller PD**. (Guest Editor). The Osteoporosis Reports. From the 30<sup>th</sup> Annual Meeting of the American Society of Bone and Mineral Research 2008; 1(1): 1-22.
  215. Satterwhite J, Heathman M, **Miller PD**, Marin F, Glass EV, Dobnig H. Pharmacokinetics of recombinant human parathyroid hormone 1-34 {rhPTH(1-34)} and calcium pharmacodynamics in postmenopausal women *Calcif issue Internat* 2010 (in press).
  216. Sunyecz JA, Silverman SL, Barr CE, **Miller PD**. Efficacy of monthly oral ibandronate: evidence from clinical trials, meta-analyses, and observational studies. *ObGyn* 2009 (in press).
  217. Baim SR and **Miller PD**. The role of serum C-telopeptide (CTX) in the management of postmenopausal osteoporosis and its use in predicting osteonecrosis of the jaw (ONJ). *J Bone Miner Res* 2009; 24(4): 561-574.
  218. **Miller PD**. Denosumab-anti-rank ligand antibody. *Current Osteoporosis Reports* 2009; 7: 18-22.
  219. Recker RR, Lewiecki EM, **Miller PD**, Reiffel J. Safety of bisphosphonates in the treatment of osteoporosis. *Am J Med* 2009; 122 (2A): S22-S32.
  220. Watts NB, **Miller PD**, Kohlmeier LA, Sebba A, Chen P, Wong M, and Krohn K. Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment. *J Bone Miner Res* 2009; 24:
  221. **Miller PD**. Diagnosis and treatment of osteoporosis in chronic renal disease. *Seminars Nephrol* 2009; 29 (2): 144-155.
  222. WattsNB, Lewiecki EM, Bonnicks SL, Laster AJ, Binkley N, Blank RD, Geusens PP, **Miller PD**, Petak SM, Recker RR, Saag KG, Schousboe J, Siris ES, and Bilizikian JP. Perspective: Clinical value of monitoring BMD in patients treated with bisphosphonate for osteoporosis. *J Bone Miner Research*. 2009; 24 (10): 1643-1646.
  223. McClung MR, **Miller PD**, Recknor C, Mesenbrink P, Bucci-Rechtweg C, Benhamou CL. Zoledronic acid for the prevention of bone mass: a randomized controlled trial. *Obstetrics and Gynecology* 2009; 114: 999-1007.
  224. Cranney A, Wells,GA, Yetsir E, Adami S, Cooper C, Delmas PD, **Miller PD**, Papapoulos S, Reginster JY, Sambrook PN, Silverman S, Siris E, Adach JD. *Osteoporosis Int*. 2009; 20(2): 291-297.
  225. **Miller PD**, Wagman R, Peacock M, Lewiecki EM, Bolognese M, Weinstein R, Ding B, San Martin J, McClung MR. Effect of Denosumab on Bone Mineral Density, Biochemical Markers of Bone Turnover, and Safety: 6-Year Results of a Phase 2 Clinical Trial. *J Clin Endo Metabolism* 2010;
  226. **Miller PD**. Fragility fractures in chronic kidney disease: an opinion-based approach. *Cleveland Clinic Journal of Medicine* 2009; 76: 715-723.

227. Lewiecki EM, Bilezikian JP, Laster AJ, **Miller PD**, Recker RR, Russell RGG, and Whyte MP. 2009 Santa Fe Bone Symposium. *J Clin Densit* 2010; 13: 1-9.
228. Watts NB, Lewiecki EM, Bonnick SL, Laster AJ, Binkley N, Blank RD, Geusens PP, **Miller PD**, Recker RR, Saag KG, Schousboe J, Siris ES, Bilezikian JP. Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis. *J Bone Miner Res* 2009; 24 (10): 1643-1646.
229. **Miller PD** and Derman R. What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis? *Osteoporosis Internat* 2010; (in press).
230. Orwoll ES, **Miller PD**, Adachi JD, Brown J, Adler R, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrick P, Weinstein R. Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5mg versus a once weekly 70 mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active controlled study. *J Bone Miner Res* 2010; 25: 2239-2250.
231. Sajjan S, Barrett-Connor E, McHorney C, **Miller PD**, Shuvayu Sen S, Etch Siris. Rib Fracture as a Predictor of Future Fractures in Young and Older Postmenopausal Women: Results from the National Osteoporosis Risk Assessment (NORA). *Osteo Internat*. 2012; 23(3): 821-888.
232. Blank RD, Bilezikian JP, Bonnick SL, Laster AJ, Leib ES, Lewiecki EM, **Miller PD**, Watts NB, Binkley N. "Evidence-based" or "logic-based" medicine. *Osteoporosis Internat* 2010; 21: 1681-1684.
233. **Miller PD**. All bisphosphonates are (or may not be) the same: potential reasons for clinical differences. *J Women's Health*. 2010; 19 (4): 665-669.
234. Hochberg MC, Silverman SL, Barr CE and **Miller PD**. The utility of changes in serum levels of C-terminal telopeptide of type I collagen in predicting patient response to oral monthly ibandronate. *J Clin Densit* 2010; 13(2): 181-189.
235. Reid IR, **Miller PD**, Brown JP, Kendler DL, Fahrleitner-Pammer, Valter I, Maasalu K, Bolognese MA, Woodson G, Bone H, Ding B, Wagman RB, San Martin J, Ominsky MS, Dempster DW, on behalf of the Denosumab Phase 3 Bone Histology Study Group. Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies. *J Bone and Min Res* 2010; 25: 2256-2265.
236. **Miller PD** and Trippe K. Osteoporosis and chronic kidney disease. National Osteoporosis Foundation Clinical Updates. 2010.
237. Bone HG, Bolognese MA, Yuen CK, Kendler DL, **Miller PD**, Yang YC, Grazette L, San Martin J, and Gallagher CJ. Effects of Denosumab Treatment and Discontinuation on

- Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass. *J Clin Endocrinol Metab.* 2011; 96:972-980.
238. Cummings SR, McClung M, Reginster JY, Cox D, Mitlak B, Stock J, Amewou-Atisso M, Powles T, **Miller PD**, Zanchetta J, Christiansen C. Arzoxiphene for prevention of fractures and invasive breast cancer in postmenopausal women. *JBMR* 2010 (online).
239. Cosman F, Eriksen EF, Recknor C, **Miller PD**, Guanabens N, Kasperk C, Papanastaiou P, Readie A, Rao H, Buccui-Rechtweg C, Boonen S. Effects of intravenous zoledronic acid plus subcutaneous teriparatide (1-34) rPTH in postmenopausal osteoporosis. *J Bone Miner Res* 2011; 26 (3): 503-511.
240. **Miller PD**, Delmas PD, Huss H, Patel KM, Schimmer RC, Adami S, Recker RR. Increases in hip and spine bone mineral density are predictive of antifracture efficacy with ibandronate. *Calcif Tissue Internat* 2010; 87:305-313.
241. **Miller PD**, Wagman RB, Peacock M, Lewiecki EM, Bolognese MA, Weinstein RL, Martin JS, and McClung MR. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. *JCEM* 2011; 96 (2):
242. **Miller PD**. The Kidney and Bisphosphonates. *BONE* 2011; 49(1): 77-81.
243. McClung MR, **Miller PD**, Brown JP, Zanchetta J, Bolognese MA, Benhamou CL, Balske A, Burgio DE, Sarley J, McCullough MS and Recjer RR. Efficacy and safety of a novel Delayed-release Risedronate 35 mg once-a-week tablet. (NOW). *Osteoporosis Internat.* 2012; 23(1): 267-276.
244. Jamal SA, Ljunggren O, Stehman-Breen C, Cummings SR, McClung MR, Goemaere S, Ebeling PR, Franek E, Yang Y, Egbuna OI, Boonen S, **Miller PD**. The Effects of Denosumab on Fracture and Bone Mineral Density by Level of Kidney Function. *J Bone Miner Res.* 2011; 26(8): 1829-1835.
245. Lewiecki EM, Compston JE, **Miller PD**, Adachi JD, Adams JE, Leslie WD, Kanis JA, Moayyeri A, Adler RA, Hans DB, Kendler DL, Diez-Perez A, Krieg MA, Masri BK, Lorenc RR, Bauer DC, Blake GM, Josse RG, Clark P, Kahn AA on behalf of the FRAX Position Development Members. *J Clin Densit* 2011; 14(3): 1-11.
246. **Miller PD**, Ragi-Eis S, Mautalen C, Raimeriz F, Jonkamski I. Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease-the DIVINE study. *BONE* 2011; 49 (6): 1317-1322.
247. **Miller PD**, Recker R, Reginster JY, Ris BJ, Czerwinski E, Masanauskaite D, Kenwright A, Lorenc R, Stakkestad JA, Lakatos P. Efficacy of monthly oral ibandronate is sustained over 5 years" the MOBILE long-term extension study. *Osteoporosis Internat.* 2012; 23(6): 1747-1756.
248. **Miller PD**. Denosumab-A review. *Therapeutic Advances in Musculoskeletal Diseases.* 2011; 3 (6): 271-282.
249. **Miller PD**. Vitamin D, calcium, and Cardiovascular Mortality- A Review. *Endocrine Practice.* 2011; 17 (5): 798-806.



250. **Miller PD**. Diseases of mineral metabolism: new and emerging therapeutics for osteoporosis. *Metabolic Bone Functions and Modulators*. 2011 (in press).
251. Sunyecz JA, Silverman SL, Barr CE and **Miller PD**. Efficacy of once-monthly oral ibandronate: clinical trials, meta-analysis, and database studies. *Clinical Interventions in Aging*. 2011 (in press).
252. Reid IR, Lyles K, Su G, Brown JP, Walsh JP, Del Pino-Monte J, **Miller PD**, Fraser WD, Cafoncelli S, Bucci-Rechtweg C, Hosking DL. A single infusion of zoledronic acid produces sustained remission in Paget's disease: Data to 6.5 years. *J Bone Miner Res* 2011; 26(9): 2261-2270.
253. Lewiecki EM, Bilezikian JP, Khosla S, Marrcus R, McClung, **Miller PD**, Watts NB, Maricic M. Osteoporosis Update from the 2010 Santa Fe Bone Symposium. *J Clin Densit* 2011; 14(1): 1-21.
254. Jamal S, West S and **Miller PD**. Bone and Kidney Disease: Diagnostic and Therapeutic Implications. *Current Rheumatology Reports*. 2011 (in press).
255. **Miller PD**. Thanks and Best Wishes (editorial). *J Clin Densit* 2011; 14(4): 1-4
256. **Miller PD**, Jamal S, West S. Bone mineral density in chronic kidney disease-use and misuse. *Clin Rev Bone and Mineral Metab*. 2012; (in press).
257. Jamal S, West S, **Miller PD**. Fracture risk assessment in patients with chronic kidney disease. *Osteoporosis Internat* 2012 (in press).
258. **Miller PD**, Jamal S, Boonen S, Evenepoel P, Eastell R. Renal safety in patients with osteoporosis treated with bisphosphonates: a review. *JBMR* 2013; (in press).
259. Boonen S, Ferrari S, **Miller PD**, Eriksen EF, Sambrook PN, Compston J, Reid IR, Cosman F. Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long term continuation on bone turnover and fracture risk- a perspective. *J Bone Miner Res* 2012; 27(5): 963-974.
260. Lewiecki EM, Bilezikian JP, Jankowski LG, McCloskey EV, **Miller PD**, Morgan SL, Orwoll ES, and Potts JT, Jr. Proceedings of the 2011 Santa Fe Bone Symposium. *J Clin Densit* 2102; 15(1): 1-20.
261. Kholsa S, Bilezikian JP, Dempster D, **Miller PD**, Neer R, Recker RR, Shane E, Shoback D, and Potts J, Jr. Position statement: Benefits and Risks of Bisphosphonate Therapy for Osteoporosis. *J Clin Endo Metab* 2102; 97(7): 2272-2282..
262. McClung M, Bauer D, Davison KS, Dian L, Hanley DA, Harris ST, Kendler DL, Lewiecki EM, McClung MR, **Miller PD**, Yuen CK. Benefits and risks of bisphosphonates for the treatment of postmenopausal osteoporosis and the rationale for a drug holiday. *Am J. Med*; 126 (1): 13-20.
263. Bauer D, Davison KS, Dian L, Hanley DA, Harris ST, Kendler EM, Lewiecki EM, McClung MR, **Miller PD**, Yuen CK. Conveying benefits and risk of postmenopausal osteoporosis therapies. *Am J Med* 2012 (in press).
264. Lewiecki EM, Laster AJ, **Miller PD**, Bilezikian JP. More bone density testing is needed, not less. *J Bone Miner Res* 2013; 126 (1): 13-20.

265. Bauer D, Krege J, Lane N, Leary E, Libanati C, **Miller PD**, Meyers G, Silverman S, Vesper HW, Lewe D, Payette M, Randall S. National Bone Health Alliance Bone Marker Turnover Project: Current Practices and the Need for U.S. Harmonization, Standardization and Common Reference Ranges Osteoporosis Internat 2102 (in press).
266. Lewiecki EM and **Miller PD**. Skeletal effects of primary hyperparathyroidism: bone mineral density and fracture risk. *J Clin Densit* 2013; 16 (1): 28-32.
267. **Miller PD**. Osteoporosis in patients with chronic kidney disease: diagnosis, evaluation and management. Up-to-Date, Basow DS (Ed), UpToDate, Waltham, MA, 2013.
268. Jamal S and **Miller PD**. Secondary and tertiary hyperparathyroidism. *J Clin Densit* 2013; 16 (2): 1-5.
269. Dempster DW, Zhou H, Recker RR, Brown J, Bolognese MA, Recknor CP, Kendler DL, Lewiecki EM, Hanley DA, Rao DS, **Miller PD**, Woodson GC, Lindsay R, Binkley N, Wan X, Ruff V, Janos B, Taylor KA. Skeletal histomorphometry in subjects in teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial. *J Clin Endocrinol Metab*. 2012; 97 (8): 2799-2808.
270. Jamal SA, West SL, **Miller PD**. Bone and kidney disease: diagnostic and therapeutic implications. *Curr Rheumatol Rep*. 2012; 14:217–223.
271. **Miller PD**, Black DM, Hruska J, Boonen S. Renal effects of treatment with zoledronic acid: results from the HORIZON-PFT extension study. *Osteoporos Int*. 2012; 23:S197–S198.
272. **Miller PD**. Bone strength and surrogate markers: the first, second, and third fiddle. *J Bone Miner Res* 2012; 27 (8): 1623-1626.
273. Lewiecki EM, Adler RA, Bilezikian JP, Bouxsein ML, Marcus R, McClung MR, **Miller PD**, Tanner SB, Randall S. Osteoporosis update from the 2012 Santa Fe Bone symposium. *J Clin Densitom*. 2013; Feb 15.
274. **Miller PD**. Unrecognized and underappreciated secondary causes of osteoporosis. *Endocrinol Metab Clinics North America*. 2012; 4(3): 613-628.
275. Orwoll E, Teglbjærg CS, Langdahl BL, Chapurlat R, Czerwinski E, Kendler DL, Reginster JY, Kivitz A, Lewiecki EM, **Miller PD**, Bolognese MA, McClung MR, Bone HG, Ljunggren Ö, Abrahamsen B, Gruntmanis U, Yang YC, Wagman RB, Siddhanti S, Grauer A, Hall JW, Boonen S. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. *J Clin Endocrinol Metab*. 2012; 97(9):3161-9.
276. McClung MR, Lewiecki EM, Bolognese MA, Peacock M, Weinstein RL, Ding B, Geller ML, Grauer A, Wagman RL, and **Miller PD**. Effects of denosumab on bone mineral

density and biochemical markers of bone turnover: 8 year results of a phase 2 clinical trial. *Osteoporosis Internat.* 2013; 24(1): 227-235.

277. Lewiecki EM, **Miller PD**, and Bilezikian JP. Bone interval density and the transition to osteoporosis. *New Engl J Med.* 2012; 366 (16): 1546-1547.

### **Textbooks**

1. Schrier RW, Miller PD, Lacher JW: Diuretics and hyponatremia. International Symposium on Diuretics. Switzerland, Bockringer Mannheim, 1977, p. 183-192.
2. Schrier RW, Miller PD: Water metabolism in diabetes insipidus and the syndrome of inappropriate antidiuretic hormone secretion. IN Kurtzman N, Martinez-Maldonado M. (eds.): Renal Pathophysiology. Taylor-Brown Publishers, 1976.
3. Linas SL, Anderson RJ, Miller PD, Schrier RW: Rational use of diuretics in cirrhosis. The Kidney in Liver Disease. Epstein M (ed), Elsevier, North Holland Inc., 1978, p. 313-331.
4. Schrier RW, Cronin RE, Miller PD, deTorrente A, Burke TJ, Bulger R: Role of solute excretion in prevention of norepinephrine-induced acute renal failure. Int Symposium on Acute Renal Failure. Switzerland, 1976.
5. Miller PD: Osteoporosis and other metabolic bone diseases. Geriatric Medicine: The Care of the Elderly Patient (second edition). Schrier RW (ed), W.B. Saunders, Co., Philadelphia, PA, 1990, p. 324-340.
6. Miller PD: Clinical interpretation and utility of bone densitometry. Osteoporosis in Clinical Medicine. C.J. Rosen (ed), Humana Press Inc., Totowa, NJ, 1996, p.113-119.
7. Miller PD: Bone mass in renal disease. Osteoporosis in Clinical Medicine. C.J. Rosen (ed), Humana Press Inc., Totowa, NJ, 1996, p. 171-174.
8. Miller PD: Diagnostic prediction of increased risk of hip fracture: A clinician's perspective. Hip Fractures. Ringe J (ed), Georg Thieme Verlag, Stuttgart, 1996, p. 53-62.
9. Miller PD: Osteoporosis in the elderly. Geriatric Medicine (second edition). Jahnigen D, Schrier R (eds), Blackwell Science, Co., Cambridge, MA, PA, 1996, p. 534-557.
10. Miller PD, Harris ST. Clinical application of bone densitometry, in Bone Densitometry and Osteoporosis (eds HK Genant, G Guglielmi, M Jergas). Springer-Verlag, Berlin Heidelberg, 1998, p. 477-483.
11. Miller PD. Management of osteoporosis, in Advances in Internal Medicine (eds RW Schrier, JD Baxter, VJ Dzau, AS Fauci). Mosby, St. Louis, Missouri, 1999, p. 175-207.

12. Vecilla LS, Miller PD. Normal reference data, in Quantitative Ultrasound (eds CF Njeh, D Hans, T Fuerst, C-C Gluer, HK Genant). Martin Dunitz Ltd, London, England, 1999, p. 221-243.
13. Miller PD. Osteoporosis associated with systemic illness and medications in Atlas of Clinical Endocrinology, Volume III (ed Robert Marcus). Current Medicine, Philadelphia, PA, 2000.
14. Miller PD, Bonnick SL. Clinical application of bone densitometry in Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism 4th Edition. Lippincott Williams & Wilkins, Philadelphia, PA, 1999, p. 152-159.
15. Sterkel BB, Miller PD. Bone mass measurement techniques in clinical practice in The Osteoporotic Syndrome 4th Edition (ed: Louis Avioli). Academic Press, San Diego, CA, 2000, p. 45-66.
16. Miller PD. The treatment of osteoporosis: Antiresorptive therapy in Clinics in Laboratory Medicine (ed : Clifford Rosen). W.B. Saunders Co., Philadelphia, PA, 2000, p. 603-622.
17. Miller PD, Zapalowski C. Bone mineral density measurements in The Osteoporosis Primer (eds : Janet Henderson, David Goltzman). Cambridge University Press, Cambridge, UK, 2000, p. 262-276.
18. Masad T, Miller PD. Bone densitometry in the elderly in Manual of Bone Densitometry Measurements (ed : J.N. Fordham). Springer-Verlag London, UK, 2000, p. 199-219.
19. Miller PD. Controversial issues in bone densitometry in Principles of Bone Biology (ed J.P. Bilezikian). Academic Press, San Diego, CA, 2002, p. 1587-1597.
20. Miller PD. Paget's disease in Conn's Current Therapy (ed RE Rakel and ET Bope). W. B. Saunders Co., Philadelphia, PA, 2002, p. 598-600.
21. Miller PD. Osteoporosis in Conn's Current Therapy ( ed: RE Rakel and ET Bope). W. B. Saunders Co., Philadelphia, PA, 2002, p. 586-598.
22. Miller PD. Bone mineral density – clinical use and application in Endocrinology and Metabolism Clinics of North America (ed: JP Bilezikian). Elsevier Inc, 2003, p. 159-179.
23. Miller PD. Bone mass measurements in Clinics in Geriatric Medicine (ed: E Siris). Elsevier Inc, 2003, p. 281-297.
24. Miller PD. Bone mineral density-clinical use and applications in Clinics in Geriatric Medicine (ed: E Siris). Elsevier Inc, 2003, p. 159-179.
25. Miller PD. The clinical application of gender-based databases for the diagnosis of

- osteoporosis and fracture risk prediction. In Principles of Gender-Specific Medicine. Elsevier Inc., 2004, p. 1033-1042.
26. Miller PD. Risk factors for osteoporotic fractures. In Osteoporosis: Hot Topics, Hanley & Belfus, Philadelphia, PA, p 15-24, 2004.
  27. Miller PD. Diagnosis of osteoporosis. In Osteoporosis: Hot Topics, Hanley & Belfus, Philadelphia, PA, p 25-34, 2004.
  28. McDermott M, Zapalowski C, Miller P. Treatment of osteoporosis: Pharmacologic. In Osteoporosis: Hot Topics. Hanley & Belfus, Philadelphia, PA, p 71-109, 2004.
  29. Miller PD. Monitoring osteoporosis therapy. In Osteoporosis: Hot Topics, Hanley & Belfus, Philadelphia, PA, p 111-121, 2004.
  30. Miller PD. Bone mass measurement. In Encyclopedia of Endocrine Diseases, Elsevier Inc., 2004.
  31. Miller PD, Shane E. Management of transplantation renal bone disease: Interplay of bone mineral density and decisions regarding bisphosphonate use. In: Weir MR Medical Management of Kidney Transplantation. Philadelphia: Lippincott Williams & Wilkins, p 359-375, 2004.
  32. Miller PD and Huffer W. Renal Osteodystrophy. In: Essential Atlas of Nephrology and hypertension; 2<sup>nd</sup> edition; Eds: Schrier RW. Current Medicine, Philadelphia, Pa. 2005; pgs: 261-276.
  33. Miller PD. Osteoporosis associated with systemic illness and medications. In: Atlas of Osteoporosis. 2<sup>nd</sup> edition. Orwoll ES. Current Medicine. Philadelphia, Pa. 2003; Pgs: 120-137.
  34. Miller PD and Lerma EV. Renal bone diseases. In: The Bone and Mineral Manual-A Practical Guide. Eds: Kleerekoper M, Siris E, and McClung M. 2005; 2<sup>nd</sup> edition; Elsevier Academic Press .Burlington, MA.
  35. Miller PD. Renal Osteodystrophy. In: Rheumatology (4<sup>th</sup> edition). 2005. Eds: Ocheberg M, Silman A, Smolen J, Weinblatt M, and Weisman M. Elsevier, London, UK. Pgs:
  36. Miller PD and Leonard M. Clinical application of bone mass measurements. In Primer on Metabolic Bone Diseases. Ed. Favus M. 6<sup>th</sup> edition. Lippincott, Williams and Wilkins, Philadelphia, Pa. 2006; pgs :
  37. Miller PD. Paget's disease of bone. In Conn's Current Therapy. Eds: Rakel RE and Bope ET. Saunders (Elsevier) Philadelphia, Pa 2007; Pgs: 718-721.
  38. Camacho P and Miller PD. Osteoporosis: A Guide for Clinicians. Lippincott, Williams and

Wilkins , Philadelphia, Pa. 2007.

39. Miller PD. Combination therapy for osteoporosis: what do the data tell us? In. Osteoporosis and the Osteoporosis of Rheumatic Diseases by Lane NE and Sambrook PN. Mosby, Elsevier, Philadelphia, Pa. p 192-202.
40. Miller PD. Bisphosphonates: Pharmacology and Use in the Treatment of Osteoporosis. In. Osteoporosis. By Marcus R, Feldman D, Nelson DA, and Rosen CJ. (3<sup>rd</sup> edition). Elsevier Academic Press, San Diego , Ca. 2007. pgs: 1725-1736.
41. Faulkner KG and Miller PD. Clinical Use of Bone Densitometry . In. Osteoporosis. By Marcus R, Feldman D, Nelson DA, and Rosen CJ. (3<sup>rd</sup> edition). Elsevier Academic Press, San Diego , Ca. 2007. pgs: 1493-1515.
42. Miller PD. Renal Bone Diseases. In: Atlas of Metabolic Bone Diseases. 3<sup>rd</sup> edition. Editor: Orwoll E. Springer. NY, NY2008; pgs 135-146.
43. Miller PD. Osteoporosis in men with impaired renal function. In. Osteoporosis in Men, 2<sup>nd</sup> edition. Editors: Orwoll E, Bilezikian JP and Vanderschueren D. Elsevier, (Academic Press), San Diego, Ca 2010. Pgs. 453-465.
44. Miller PD. Renal Osteodystrophy. In . Rheumatology. Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, and Weisman MH. Mosby (Elsevier), Philadelphia, Pa. 2010. Pgs: 2013-2019.
45. Bonnicksen SL and Miller PD. Bone densitometry. In. Osteoporosis 2013. Marcus R, Feldman D, Nelson DA and Rosen C (4<sup>th</sup> edition).
46. Miller PD and Watts NB. Bisphosphonates. In. Osteoporosis 2013. Marcus R, Feldman D, Nelson DA and Rosen C , eds. (4<sup>th</sup> edition).
47. Diab D, Watts NB and Miller PD.